Gina Mauro

mRNA-4157/V940 in combination with pembrolizumab improved recurrence-free survival in patients with high-risk melanoma.

In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.

Post-hoc analysis results showed a reduction in spleen volume of 35% with ruxolitinib in patients with myelofibrosis.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.

The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.

Novel treatments are needed to replace transplant and prevent graft-vs-host disease in order to improve patient outcomes.

Regardless of prior therapies, brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, according to subgroup analyses of the phase 3 ZUMA-3 trial.

The combination of zolbetuximab and mFOLFOX6 prolonged survival in patients with CLDN18.2+ advanced gastric gastroesophageal junction adenocarcinoma, according to the phase 3 data from the SPOTLIGHT trial.

Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.

According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.

In the ECOG-ACRIN E1910 study, blinatumomab with consolidation chemotherapy extended overall survival in patients with MRD-negative B-cell acute lymphoblastic leukemia.

The MOMENTUM trial continues to show positive results for momelotinib fro the treatment of anemic myelofibrosis.

COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.

Olverembatinib is efficacious and well tolerated in tyrosine kinase inhibitor-resistant CML-CP and CML-AP patients with a BCR-ABL1 T315I mutation.

Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Retrospective data signal that transplant with a matched sibling donor may prolong survival over haploidentical stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.

Sotorasib continues to wow in the phase 1/2 CodeBreaK 100 trial of patients with KRAS G12C–mutant non–small cell lung cancer.

Results from 3 clinical trials show that adjuvant CDK4/6 inhibition is a good option for early-stage hormone-receptor-positive breast cancer.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.

Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.

Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

In a presentation during the 39th Annual Chemotherapy Foundation Symposium, Bhavana Pothuri, MD, MS, explained the recent advances in subtypes and treatment options for patients with endometrial cancer.

In the MEDALIST analysis that was presented at the 2021 ASH Annual Meeting, investigators sought to further characterize the effects of luspatercept in patients with low-risk myelodysplastic syndrome.

Updated results from CARTITUDE-1 reveal deep and durable response to ciltacabtagene autoleucel treatment in patients with multiple myeloma.

Phase 3 ZUMA-7 study results indicate that axicabtagene ciloleucel may achieve longer event-free survival compared with standard chemotherapy.

Patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome had higher mortality rates after being diagnosed with COVID-19 than those with COVID-19 who did not have cancer.